Breaks Categories: News

TuesdayOct 11, 2016 11:17 am

Nova LifeStyle, Inc. (NVFY) Trades 23% Higher on $15M Supply Agreement

Nova LifeStyle (NASDAQ: NVFY), a modern life style furniture company, this morning announced its $15 million annual product framework agreement with the Future Biz School (“FBS”) (www.futurebizschool.com), a Hong Kong and Malaysia-based professional training institute. Per the agreement, Nova LifeStyle will supply U.S.-made mattresses and other products to FBS, with actual sales subject to and fulfilled by specific orders from FBS. Nova LifeStyle said it has received “firm orders” for October and November of 2016 to supply $2 million worth of products. To view the full press release, visit: http://nnw.fm/L0kfJ About Nova LifeStyle Nova LifeStyle, Inc., a NASDAQ Global Markets…

Continue Reading

MondayOct 10, 2016 12:23 pm

OurPet’s Company (OPCO) Partners with Paulee Cleantec Ltd. to Create Eco-Friendly Waste Management Solutions

OurPet’s Company (OTCQX: OPCO) today announced that it has teamed up with Israel-based Paulee Cleantec, an international leader in eco-friendly solutions for the management of human and animal waste, calling the new partnership a “viable catalyst of major innovative solutions to the environmental concerns of pet waste management.” Paulee Cleantec has developed a patented waste system to rapidly convert animal feces into an odor-free ash fertilizer, thereby reducing the damaging impact of pet waste management on the environment. The partnership will leverage both companies’ innovations to commercialize an initial, portable dog waste product, as well as to apply the technology…

Continue Reading

MondayOct 10, 2016 11:58 am

CytRx Corporation (CYTR) Presents Interim Clinical Trial Results for Aldoxorubicin Combination

CytRx (NASDAQ: CYTR) today presented interim results from its ongoing phase 1b/2 trail of aldoxorubicin in combination with ifosfamide/mesna in patients with advanced sarcomas, pushing shares higher in morning trade. At the European Society for Medical Oncology (ESMO) 2016 Congress being held in Copenhagen, Denmark, CytRx reported that: over 25% of sarcoma patients achieved a partial response for the target lesion while 61% had prolonged stable disease; six patients with unresectable tumors achieved greater than 50% tumor shrinkage, allowing some of them to become eligible for surgery; and there were no signs of cardiotoxicity, including in patients that received approximately…

Continue Reading

MondayOct 10, 2016 11:56 am

MobileIron, Inc. (MOBL) Boosts Q3 Guidance, Shares Climb

Shares of MobileIron (NASDAQ: MOBL) are trading higher this morning after the stand-alone enterprise mobility management (EMM) provider raised guidance its guidance for the third quarter ended September 30, 2016, and said it is “on track” to be cash flow positive by the fourth quarter. Gross billings for the third quarter of 2016 are expected to be in the range of $46.5 million-$47.5 million, above the company's previous guidance of $43 million-$45 million. MobileIron said it now expects revenues between $41.0 million-$42.0 million, above the previous guidance of $39 million-$41 million. Non-GAAP operating expenses are expected to be at the…

Continue Reading

MondayOct 10, 2016 11:53 am

Net Element, Inc. (NETE) Subsidiary Retained by Market-Leading Courier Service in Kazakhstan

Net Element, Inc. (NASDAQ: NETE) this morning announced that its PayOnline subsidiary has signed an agreement with ExLine, a leading provider of courier and delivery services, freight forwarding and other related services in Kazakhstan in Central Asia, making PayOnline’s payment services available to more than 50,000 of ExLine’s customers. Per the agreement, PayOnline has implemented a custom payment solution which includes an invoice number on the secure payment page and 24/7 customer support. Payments are accepted in Kazakhstan's national currency, Russian rubles, U.S. dollars and euros. To view the full press release, visit: http://nnw.fm/pTy2o About Net Element, Inc. Net Element,…

Continue Reading

FridayOct 07, 2016 2:42 pm

Alcobra (ADHD) Issues Update on FDA Communications Regarding MEASURE Study

Alcobra Ltd. (NASDAQ: ADHD), an emerging pharmaceutical firm focused on the development of novel medications to treat cognitive disorders such as Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, announced earlier today that it has received a full clinical hold notice from the U.S. Food and Drug Administration’s Division of Psychiatry Products regarding its phase III clinical study of Metadoxine Extended Release (MDX) for the treatment of ADHD in adult patients. The letter indicates that the FDA hold in in response to electrophysiological neurologic findings in previously submitted long-term animal studies of Metadoxine. The FDA has recommended that Alcobra…

Continue Reading

ThursdayOct 06, 2016 12:35 pm

Capstone Turbine Corp. (CPST), Sky Solar Holdings, Ltd. (SKYS) Sign Financing Agreement of up to $50M

Capstone Turbine (NASDAQ: CPST) this morning announced its strategic financing relationship agreement with Sky Solar Holdings (NASDAQ: SKYS) and Sky Capital America, Inc., a Sky Solar subsidiary, to provide funding to Capstone Turbine’s Capstone Energy Finance (“CEF”) joint venture. Among other terms of the agreement, Sky Group has first right of refusal to provide funding of up to $50 million, which may be extended by an additional $100 million at Sky Group’s sole discretion for various CEF projects on a global basis after Capstone and CEF have exhausted internal funding sources of up to $25 million. “Capstone’s new finance subsidiary…

Continue Reading

ThursdayOct 06, 2016 12:34 pm

Jaguar Animal Health, Inc. (JAGX) Signs LOI for Proposed Merger with Napo Pharmaceuticals, Inc.

Jaguar Animal Health (NASDAQ: JAGX) this morning announced its non-binding letter of intent with Napo Pharmaceuticals in a potential merger deal centered on Napo’s FDA-approved crofelemer for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Napo focuses on human product development and commercialization of proprietary pharmaceuticals, and has provided Jaguar with exclusive worldwide rights for veterinary applications to crofelemer – which is also the active pharmaceutical ingredient (API) in Jaguar’s lead prescription drug candidate, Canalevia™ for the treatment of various forms of diarrhea in dogs - as well as corresponding rights to all related Napo…

Continue Reading

ThursdayOct 06, 2016 12:32 pm

Inventergy Global, Inc. (INVT) Prices $6M Public Offering

As part of its plan of compliance with NASDAQ, Inventergy Global, Inc. (NASDAQ: INVT) this morning priced a registered public offering of $1 per common stock and warrant for gross proceeds of approximately $6.0 million. The IP company said it plans to use the net proceeds of the offering to redeem a portion of its outstanding Series C and Series E preferred stock and to fund operations. Company management also expects that approximately $5.3 million of the public offering will result in the company's stockholders' equity exceeding the NASDAQ requirement of $2.5 million. The warrants are exercisable immediately and for…

Continue Reading

WednesdayOct 05, 2016 12:51 pm

Amedica Corporation (AMDA) Cuts Workforce by 38%

Amedica Corporation (NASDAQ: AMDA), a technology company that manufactures and commercializes silicon nitride ceramic for biomedical applications, this morning announced that it has reduced its workforce by approximately 38% to lower its operating expenses. Amedica said it expects the reduction to save roughly $2 million on an annualized basis. Severance-related costs of approximately $465,000 will be recorded in Q4 2016. "We acknowledge the hard work of those affected by this decision, towards bringing silicon nitride technology to patient care," Dr. Sonny Bal, chairman and CEO of Amedica, stated in the news release. "Consistent with our previously-announced commitments, this prudent course,…

Continue Reading